First results from the phase III READY-4 trial demonstrate the long-term safety of repeated injections of RelabotulinumtoxinA for both frown lines and crow’s feet, with efficacy and patient ...

Immigrants’ rights groups have spent the last year preparing for a second Trump term and an overhaul of ... prepared than they were in 2016 — ready to move quickly depending on how the ...

Galderma today announced new phase III data from the READY-4 clinical trial, demonstrating the long-term safety of RelabotulinumtoxinA (Relfydess ™) for frown lines and crow’s feet after ...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma today announced new phase III data from the READY-4 clinical trial, demonstrating the long-term safety of RelabotulinumtoxinA (Relfydess ™) for frown ...